Company Profile
Bone Biologics Stock Price, News & Catalysts
- Ticker:
- BBLG
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.48 USD (-1.17%)
Close
Last updated: October 6, 2026
2.28M USD
Market cap
Why the stock is moving
As of Oct 6, 2026, BBLG closed down 1.17% at $0.4795. No new same-company headline was identified in the current news window.
Company overview
Orthobiologic Product Developer
Bone Biologics develops biologic products intended to improve bone formation in spinal fusion. Its lead candidate combines a recombinant growth factor with a commonly used bone-graft material.
NB1 Bone Graft Candidate
NB1 combines recombinant human NELL-1 protein with demineralized bone matrix. NELL-1 is intended to promote targeted bone formation while the matrix provides a scaffold for new tissue growth.
Lumbar Fusion Pilot Study
The first-in-human clinical study is evaluating NB1 in patients undergoing transforaminal lumbar interbody fusion for degenerative disc disease. The trial compares the product's safety and fusion performance with standard grafting approaches.
Pivotal Development Path
The pilot design was reviewed with the FDA and is intended to inform a later U.S. pivotal study. Clinical evidence from Australia will help determine sample size, endpoints, and the broader regulatory strategy.
Manufacturing and Product Stability
Bone Biologics is developing manufacturing, quality, and storage processes for recombinant NELL-1. Extending validated shelf life improves the practicality of supplying clinical sites and future commercial customers.
Future catalysts
- Completion of enrollment in the first-in-human NB1 pilot study by the end of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Bone Biologics (BBLG)?
Bone Biologics (BBLG) most recently closed at 0.48 USD, a -1.17% move versus the previous session.
What is the market cap of Bone Biologics (BBLG)?
Bone Biologics currently has a market capitalization of 2.28M USD on BioPharmSignal.
What does Bone Biologics do?
Orthobiologic Product Developer Bone Biologics develops biologic products intended to improve bone formation in spinal fusion. Its lead candidate combines a recombinant growth factor with a commonly used bone-graft material. NB1 Bone Graft Candidate NB1 combines recombinant human NELL-1 protein with demineralized bone matrix. NELL-1 is intended to promote...
On which exchange is BBLG stock listed?
Bone Biologics (BBLG) is associated with NASDAQ, United States, Biopharma.
What is NELL-1?
NB1 Bone Graft Candidate NB1 combines recombinant human NELL-1 protein with demineralized bone matrix.
Which conditions is Bone Biologics targeting with NELL-1?
Orthobiologic Product Developer Bone Biologics develops biologic products intended to improve bone formation in spinal fusion. Its lead candidate combines a recombinant growth factor with a commonly used bone-graft material. NB1 Bone Graft Candidate NB1 combines recombinant human NELL-1 protein with demineralized bone matrix. NELL-1 is intended to promote...
How does Bone Biologics describe recent progress with NELL-1?
Completion of enrollment in the first-in-human NB1 pilot study by the end of 2026.
What is Orthobiologic?
Orthobiologic Product Developer Bone Biologics develops biologic products intended to improve bone formation in spinal fusion.